Disease · MONDO_0005203
Comparisons in its trials14
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 14 of 14
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| C1-Inhibitor (Berinert) (Human) (C1INH) vs Normal Saline: Mean Number of Patients on Dialysis | 0 of 35 | 5 of 35 | 70 | NCT02134314 | Trial comparisons |
| C1-Inhibitor (Berinert) (Human) (C1INH) vs Normal Saline: Number of Patients With Serum Creatinine Reduction Ratio of < 30% From 24 to 48 Hours Post-transplant. | 30 of 35 | 28 of 35 | 70 | NCT02134314 | Trial comparisons |
| C1-Inhibitor (Berinert) (Human) (C1INH) vs Normal Saline: Graft Survival | 34 of 35 | 34 of 35 | 70 | NCT02134314 | Trial comparisons |
| C1-Inhibitor (Berinert) (Human) (C1INH) vs Normal Saline: Patient Survival | 35 of 35 | 35 of 35 | 70 | NCT02134314 | Trial comparisons |
| C1-Inhibitor (Berinert) (Human) (C1INH) vs Normal Saline: deaths from any cause | 0 of 35 | 0 of 35 | 70 | NCT02134314 | Trial comparisons |
| C1-Inhibitor (Berinert) (Human) (C1INH) vs Normal Saline: serious adverse events | 10 of 35 | 10 of 35 | 70 | NCT02134314 | Trial comparisons |
| C1-Inhibitor (Berinert) (Human) (C1INH) vs Normal Saline: Number of Patients With Delayed Graft Function (DGF) (Categorized by DGF Scale) | 15 of 34 | 21 of 35 | 69 | NCT02134314 | Trial comparisons |
| C1-Inhibitor (Berinert) (Human) (C1INH) vs Normal Saline: Number of Patients Enrolled Who Require at Least One Session of Dialysis in the First 7 Days Post Transplant. | 15 of 34 | 21 of 35 | 69 | NCT02134314 | Trial comparisons |
| C1-Inhibitor (Berinert) (Human) (C1INH) vs Normal Saline: Number of Patients Enrolled With Serum Creatinine >3mg/dL on Postoperative Day 5. | 29 of 34 | 32 of 35 | 69 | NCT02134314 | Trial comparisons |
| Periostat vs Placebo Oral Tablet: deaths from any cause | 0 of 20 | 0 of 22 | 42 | NCT00246740 | Trial comparisons |
| Periostat vs Placebo Oral Tablet: serious adverse events | 0 of 20 | 0 of 22 | 42 | NCT00246740 | Trial comparisons |
| Nitric Oxide on CPB vs Control: Surgical Morbidity | 0 of 12 | 0 of 12 | 24 | NCT02151877 | Trial comparisons |
| Nitric Oxide on CPB vs Control: deaths from any cause | 0 of 12 | 0 of 12 | 24 | NCT02151877 | Trial comparisons |
| Nitric Oxide on CPB vs Control: serious adverse events | 0 of 12 | 0 of 12 | 24 | NCT02151877 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005203/comparisons